Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,392 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions
Ruvidar® (TLD-1433) bladder infusion and PDT
Combination Product
Lead sponsor
Theralase® Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Renal Carcinoma, Renal Mass
Interventions
Robot-Assisted Laparoscopic Surgery, High-Intensity Focused Ultrasound Ablation, Therapeutic Laparoscopic Surgery, Sonatherm 600i Ultrasonic Lesion Generating System
Procedure · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Anemia of Chronic Kidney Disease
Interventions
ferric citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Phoenix, Arizona • Tempe, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Endometrial Cancer
Interventions
ctDNA Testing, Blood draw
Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Kidney Cancer
Interventions
Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Ovarian Neoplasms
Interventions
AMG 479
Biological
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Bakersfield, California • Fullerton, California • La Verne, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Leukemia, Lymphoma, Oral Complications
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
Conditions
Contraception
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
49
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Meridian, Idaho • Neptune City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Kidney Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions
docetaxel, tariquidar, 99mTc-sestamibi imaging
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Urinary Incontinence
Interventions
Pelvic Floor Muscle exercises
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced May 21, 2026, 8:08 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers
Conditions
Surgical Site Infection Following Cesarean Delivery
Interventions
Mepilex Ag Dressing, Standard Surgical Dressing (Telfa non-adhesive dressing, gauze, and Primapore adhesive bandage)
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 2 Interventional Results available
Conditions
Recurrent Ovarian Epithelial Cancer
Interventions
oxaliplatin, topotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
PS-002
Genetic
Lead sponsor
Purespring Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
16
States / cities
Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Ovarian Cancer, Neoplasms, Carcinoma
Interventions
enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced May 21, 2026, 8:08 PM EDT
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Interventions
Cisplatin, No treatment
Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
59
States / cities
Duarte, California • La Jolla, California • Newport Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Ramucirumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
11
States / cities
Hollywood, Florida • Orlando, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced May 21, 2026, 8:08 PM EDT